Go Pro

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific logo
$51.77 +0.08 (+0.15%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$52.32 +0.55 (+1.07%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
2
Hold
5
Buy
24

Based on 31 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 31 analysts, 2 have given a sell rating, 5 have given a hold rating, and 24 have given a buy rating for BSX.

Consensus Price Target

$71.62
38.34% Upside
According to the 31 analysts' twelve-month price targets for Boston Scientific, the average price target is $71.62. The highest price target for BSX is $118.00, while the lowest price target for BSX is $50.00. The average price target represents a forecasted upside of 38.34% from the current price of $51.77.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BSX Analyst Ratings Over Time

TypeCurrent Forecast
8/16/25 to 8/16/26
1 Month Ago
7/17/25 to 7/17/26
3 Months Ago
5/18/25 to 5/18/26
1 Year Ago
8/16/24 to 8/16/25
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
3 Strong Buy rating(s)
Buy
24 Buy rating(s)
23 Buy rating(s)
23 Buy rating(s)
20 Buy rating(s)
Hold
5 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$71.62$79.84$92.83$117.50
Forecasted Upside38.34% Upside81.65% Upside66.18% Upside13.91% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyBuy

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Boston Scientific Stock vs. The Competition

TypeBoston ScientificHealthcare CompaniesBroader Market
Consensus Rating Score
2.71
2.30
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside38.34% Upside785.25% Upside11.05% Upside
News Sentiment Rating
Positive News

See Recent BSX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
7/31/2026
Argus logo
Argus
3 of 5 stars
David Toung
3 of 5 stars
Reiterated RatingBuyHold
7/30/2026
Shagun Singh
3 of 5 stars
Lower TargetOutperform$85.00 ➝ $70.00+54.19%
7/30/2026
UBS Group AG logo
UBS Group
4 of 5 stars
Patrick Wood
Not Rated
Lower TargetBuy$74.00 ➝ $67.00+47.58%
7/30/2026 Reiterated RatingBuy$60.00+34.09%
7/30/2026Set Target$56.00+21.57%
7/30/2026Lower TargetBuy$70.00 ➝ $66.00+47.50%
7/30/2026Lower TargetEqual Weight$55.00 ➝ $50.00+8.54%
7/30/2026Set Target$60.00+30.25%
7/30/2026Lower TargetBuy$70.00 ➝ $61.00+32.42%
7/30/2026Reiterated RatingOutperform$57.00+23.74%
7/30/2026Lower TargetBuy$61.00 ➝ $56.00+23.17%
7/30/2026Lower TargetBuy$62.00 ➝ $57.00+26.36%
7/29/2026Set Target$60.00+30.25%
7/29/2026Lower TargetBuy$65.00 ➝ $60.00+29.99%
7/27/2026Lower TargetOutperform$90.00 ➝ $85.00+89.56%
7/15/2026Lower TargetOutperform$90.00 ➝ $70.00+63.75%
7/8/2026Lower TargetBuy$77.00 ➝ $57.00+25.84%
7/7/2026 DowngradeHold (C-)Sell (D+)
7/6/2026 Set Target$65.00+47.17%
6/24/2026Lower TargetBuy$100.00 ➝ $67.00+49.84%
6/12/2026 Reiterated RatingOverweight$65.00+37.67%
6/5/2026 DowngradeHoldStrong Sell
5/29/2026DowngradeOutperformPeer Perform
5/28/2026Set Target$71.00+44.81%
5/28/2026Lower TargetOverweight$96.00 ➝ $89.00+76.79%
5/18/2026Lower TargetBuy$105.00 ➝ $68.00+22.86%
4/29/2026 DowngradeStrong-BuyHold
2/6/2026Reiterated RatingOutperform$112.00+43.53%
2/5/2026Lower TargetOverweight$135.00 ➝ $100.00+27.61%
2/5/2026Lower TargetOverweight$130.00 ➝ $118.00+56.29%
2/2/2026 Set Target$115.00+24.35%
10/3/2025 DowngradeBuyHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:52 AM ET.


Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 10, 2026. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • Boston Scientific Co. has demonstrated strong revenue growth, with a recent increase of 7.5% year-over-year, indicating robust demand for its medical devices.
  • The company has initiated a significant share repurchase plan, allowing for the buyback of $5.00 billion in outstanding shares, which often signals that the management believes the stock is undervalued.
  • Analysts have a positive outlook, with a consensus target price around $71.62, suggesting potential upside for investors.
  • Boston Scientific Co. has set its earnings per share (EPS) guidance for Q3 2026 at 0.800-0.820, reflecting confidence in its financial performance.
  • The current stock price is around $60, which may present a buying opportunity for investors looking to enter at a favorable valuation.

Boston Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • Several analysts have recently downgraded their price targets for Boston Scientific Co., indicating a cautious sentiment in the market.
  • Despite the revenue growth, the company faces intense competition in the medical device sector, which could impact its market share and profitability.
  • Institutional investors hold a significant 89.07% of the company's stock, which may lead to volatility if large shareholders decide to sell.
  • Recent reports suggest that some analysts have lowered their ratings, which could affect investor confidence and stock performance.
  • The medical device industry is subject to regulatory scrutiny, and any changes in regulations could pose risks to Boston Scientific Co.'s operations and growth prospects.

BSX Forecast - Frequently Asked Questions

According to the research reports of 31 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $71.62, with a high forecast of $118.00 and a low forecast of $50.00.

31 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 24 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BSX shares.

According to analysts, Boston Scientific's stock has a predicted upside of 38.34% based on their 12-month stock forecasts.

Over the previous 90 days, Boston Scientific's stock had 4 downgrades by analysts.

Analysts like Boston Scientific more than other "healthcare" companies. The consensus rating for Boston Scientific is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how BSX compares to other companies.


This page (NYSE:BSX) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners